Stock Options (Details Textual) (USD $)	3 Months Ended	6 Months Ended		3 Months Ended	6 Months Ended	1 Months Ended	6 Months Ended	8 Months Ended	1 Months Ended	6 Months Ended	1 Months Ended	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2012	Dec. 31, 2011	Jun. 30, 2012 Restricted Stock [Member]	Jun. 30, 2012 Restricted Stock [Member]	Sep. 30, 2011 Vesting Upon F D Clearance of Investigational Device Exemption to Permit Commencement of Human Clinical Trial [Member]	Jun. 30, 2012 Vesting Upon F D Clearance of Investigational Device Exemption to Permit Commencement of Human Clinical Trial [Member]	Apr. 30, 2012 Vesting Upon F D Clearance of Investigational Device Exemption to Permit Commencement of Human Clinical Trial [Member]	Sep. 30, 2011 Vesting Upon F D Approval of Company Biopolymer Scaffolding Device to Treat Spinal Cord Injuries [Member]	Jun. 30, 2012 2007 Plan [Member]	Sep. 30, 2011 2010 Plan [Member]	Jun. 30, 2012 2010 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options available to purchase/Common Stock outstanding	7,566,466	7,566,466	6,302,893							3,691,577		3,874,890
Shares available for future grants										0		2,625,110
Shares authorized for issuance												6,500,000
Exercisable period		6 years 29 days								10 years		10 years
Stock-based compensation expense, net of forfeitures				$ 530,413	$ 767,955
Expected term of options granted				10 years	10 years
Vesting period		6 years 6 months 4 days		48 months	48 months
Restricted stock awards						30,000			50,000		80,000
Fair value of amortized stock awards								23,400
Reversed restricted stock awards							11,700
Stock Option (Textual) [Abstract]
Weighted average grant-date fair value of options granted		$ 2.54
Total fair value of options that vested	511,220
Total unrecognized compensation expense, related to non-vested share-based compensation arrangements	$ 4,005,000	$ 4,005,000
Period for unrecognized compensation expense is estimated to be recognized		3 years 1 month 6 days